Atlanta, Georgia, Friday, August 9, 2019:
US-based medical device company and producer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses Visioneering Technologies, Inc (ASX: VTI) (‘Visioneering’ or ‘the Company’) is pleased to announce that it has received a Certificate of Listing from Hong Kong’s Medical Device Control Office, Department of Health. Listing No. 190176 applies to the NaturalVue® (etafilcon A) Multifocal and NaturalVue® (etafilcon A) Sphere currently marketed by Visioneering, as well as the NaturalVue® (etafilcon A) Toric and NaturalVue® (etafilcon A) Multifocal Toric products that Visioneering plans to market in the near future. The listing covers the use of the Company’s NaturalVue® Multifocal for myopia progression control.
Visioneering sells patented revolutionary daily disposable contact lenses that address two underserved populations: presbyopia (loss of near vision in people over 40-45), and paediatric myopia (nearsightedness in children).
Strong need for myopia management solutions
With a population of almost 7.5 million people, Hong Kong is a thriving and viable market for vision correction. Researchers estimate that over 25% of 5-9 year olds in Hong Kong are myopic, and the condition worsens through adolescense such that over 90% of 20-24-year-olds have myopia. Based on these estimates, Hong Kong has one of the highest rates of myopia of any region,¹ resulting in an approximate addressable market size of nearly US$100m. Myopia increases the risk of serious ocular conditions such as cataracts, retinal detachment, glaucoma and other potentially blinding diseases.²
Data presented in January 2019 by eye care practitioners showed in 141 children wearing NaturalVue® Multifocal an average decrease of myopia progression of 90%, compared to the rate of progression prior to wearing NaturalVue®, and a 55% decrease in the pace of lengthening of the eye (n=36).³ Inhibition of myopia progression was consistent between children who had worn the lens daily for one year and those who had worn the lenses daily for up to 4 years.
Initial entry into Asia follows rapid expansion into other regions
With this Certificate of Listing in hand, the Company’s first in Asia, Visioneering will now aim to launch in Hong Kong. The Company will now work to establish a distribution partnership in anticipation of commercial launch in Hong Kong in 2019.
In the US alone, the addressable market for paediatric myopia is estimated at US$2bn per annum. Visioneering estimates the market in China to be as large as US$11bn, with sizable markets also in Japan, Korea, Southeast Asia, and Hong Kong. In just over two short years since its IPO, Visioneering has obtained clearances and launched its products for myopia progression control and presbyopia in Australia, New Zealand, the UK, and the Nordics.
Visioneering Technologies CEO Stephen Snowdy, PhD, said: “Coming off of another record quarter of sales and shipments, we’re excited by this latest development. Hong Kong is an important market for us because it represents our initial entry into Asia. While Hong Kong is a relatively small market by population, the prevalence and severity of myopia indicate a strong need for our NaturalVue® Multifocal product. We look forward to bringing our solution to the eye care professionals and patients in Hong Kong, and will now turn our efforts into solidifying the partnerships required there.”
1. Holden BA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042.
2. Flitcroft D. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Progress in Retinal and Eye Research. 2012;31(6): 622-660.
3. O’Connor B, Jeruss J, Aller T, Dillehay SM. Myopia Management with A Unique Extended Depth of Focus Contact Lens: A Case Series Analysis. Paper presented at Global Specialty Lens Symposia. January, 2018.